Literature DB >> 265748

Early deaths in acute myelogenous leukemia.

I E Smith, R Powles, H M Clink, B Jameson, H E Kay, T J McElwain.   

Abstract

In a series of 84 patients with acute myelogenous leukemia, 24 died within 6 weeks of starting treatment. Twenty of the 24 patients had failed to achieve remission at the time of death. Death was due to infection in 20 patients and in 17 of these to septicemia; but whereas severe local infection with septicemia accounted for 12 deaths, only five patients died of septicemia without local infection. Bleeding was the direct cause of death in only four patients and an associated terminal event in another three; of these four patients three had disseminated intravascular coagulopathy. Surprisingly, in this group of patients age and overall clinical status at the time of admission were of no prognostic value in the first 6-week period. The importance of drug resistent disease associated with intractable local infection as a major cause of early death is emphasized.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 265748     DOI: 10.1002/1097-0142(197704)39:4<1710::aid-cncr2820390448>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Infection during remission induction in childhood leukaemia.

Authors:  J M Chessells; A D Leiper
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

Review 2.  Mouse models for radiation-induced cancers.

Authors:  Leena Rivina; Michael J Davoren; Robert H Schiestl
Journal:  Mutagenesis       Date:  2016-05-21       Impact factor: 3.000

Review 3.  Mouse models for efficacy testing of agents against radiation carcinogenesis—a literature review.

Authors:  Leena Rivina; Robert Schiestl
Journal:  Int J Environ Res Public Health       Date:  2012-12-27       Impact factor: 3.390

Review 4.  Radiation-induced myeloid leukemia in murine models.

Authors:  Leena Rivina; Michael Davoren; Robert H Schiestl
Journal:  Hum Genomics       Date:  2014-07-25       Impact factor: 4.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.